Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
Refine search result
123 1 - 50 of 115
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Adler, Anna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Initiation of alternative pathway of complement, and development of novel liposomal coatings2023Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    The complement system is a central part of the innate immune system, and is an essential part in recognizing and clearing non/altered-self surfaces in the body. This thesis comprises of projects in which the initiation of the alternative pathway (AP) of complement in the fluid phase as well on various artificial and lipid surfaces has been studied. We have also synthesized and evaluated polymer-lipids as liposome coatings to suppress innate immune activation with focus on complement regulation.

    In paper I we investigated how “C3b-like” C3(H2O) is in regards to form an initial fluid phase AP C3 convertase. Even though C3(H2O) could form a C3 convertase, it was much slower in comparison to the convertase generated by C3b. 

    In paper II the contact activation of C3 on various artificial and lipid surfaces as a potential targeted AP activation pathway was explored. C3 bound selectively to lipid surfaces with negatively charged phospholipids and cholesterol, activated platelets and apoptotic cells. Thus, AP was initiated without prior proteolytic cleavage of C3 nor by preformed C3(H2O) on specific surfaces in a selective manner.

    In paper III and IV, synthetic phosphatidylcholine inspired polymer-lipids consisting of poly(2-methacryloyloxyethyl phosphorylcholine)-conjugated lipids (PMPC-lipids) with different degrees of MPC polymerization were synthesized. The protein adsorption, with focus on complement proteins onto the PMPC-lipids were evaluated, indicating that PMPC-lipids with a longer polymer chain are better to suppress protein adsorption. 

    In paper V fragmented heparin-conjugated (fHep) lipids were investigated for their potential ability to recruit complement regulators to a lipid bilayer surface for complement regulation. This study indicated that fHep-liposomes could recruit the main fluid phase regulator of the AP, factor H, as well as the coagulation regulator antithrombin from human plasma. 

    To conclude, the results from this thesis indicates that C3(H2O) in the fluid phase is a poor initiator of the AP, however contact activated C3 could be targeting activation pathway for the AP. We could also successfully synthesize PMPC-lipids and fHep-lipids for protein suppression and potential complement regulation on coated liposomes. 

    List of papers
    1. Assessment of the Role of C3(H2O) in the Alternative Pathway
    Open this publication in new window or tab >>Assessment of the Role of C3(H2O) in the Alternative Pathway
    Show others...
    2020 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 11, article id 530Article in journal (Refereed) Published
    Abstract [en]

    In this study we investigate the hydrolysis of C3 to C3(H2O) and its ability to initiate activation via the alternative pathway (AP) of the complement system. The internal thioester bond within C3 is hydrolyzed by water in plasma because of its inherent lability. This results in the formation of non-proteolytically activated C3(H2O) which is believed have C3b-like properties and be able to form an active initial fluid phase C3 convertase together with Factor B (FB). The generation of C3(H2O) occurs at a low but constant rate in blood, but the formation can be greatly accelerated by the interaction with various surfaces or nucleophilic and chaotropic agents. In order to more specifically elucidate the relevance of the C3(H2O) for AP activation, formation was induced in solution by repeated freeze/thawing, methylamine or KCSN treatment and named C3(x) where the x can be any of the reactive nucleophilic or chaotropic agents. Isolation and characterization of C3(x) showed that it exists in several forms with varying attributes, where some have more C3b-like properties and can be cleaved by Factor I in the presence of Factor H. However, in common for all these variants is that they are less active partners in initial formation of the AP convertase compared with the corresponding activity of C3b. These observations support the idea that formation of C3(x) in the fluid phase is not a strong initiator of the AP. It is rather likely that the AP mainly acts as an amplification mechanism of complement activation that is triggered by deposition of target-bound C3b molecules generated by other means.

    Place, publisher, year, edition, pages
    FRONTIERS MEDIA SA, 2020
    Keywords
    complement, C3, C3(H2O), C3b, alternative pathway, C3 convertase
    National Category
    Immunology
    Identifiers
    urn:nbn:se:uu:diva-410958 (URN)10.3389/fimmu.2020.00530 (DOI)000526750400001 ()32296436 (PubMedID)
    Funder
    Swedish Research Council, 2016-2075-5.1Swedish Research Council, 2016-04519
    Available from: 2020-05-28 Created: 2020-05-28 Last updated: 2024-01-17Bibliographically approved
    2. A targeted binding and activation of native C3 without proteolytic cleavage induced by contact with biosurfaces
    Open this publication in new window or tab >>A targeted binding and activation of native C3 without proteolytic cleavage induced by contact with biosurfaces
    Show others...
    (English)Manuscript (preprint) (Other academic)
    Keywords
    complement, alternative pathway, contact activated C3, thioester, biosurfaces
    National Category
    Immunology in the medical area
    Research subject
    Immunology; Immunology
    Identifiers
    urn:nbn:se:uu:diva-499228 (URN)
    Available from: 2023-03-24 Created: 2023-03-24 Last updated: 2023-03-28
    3. Synthesis of poly(2-methacryloyloxyethyl phosphorylcholine)-conjugated lipids and their characterization and surface properties of modified liposomes for protein interactions
    Open this publication in new window or tab >>Synthesis of poly(2-methacryloyloxyethyl phosphorylcholine)-conjugated lipids and their characterization and surface properties of modified liposomes for protein interactions
    Show others...
    2021 (English)In: Biomaterials Science, ISSN 2047-4830, E-ISSN 2047-4849, Vol. 9, no 17, p. 5854-5867Article in journal (Refereed) Published
    Abstract [en]

    Poly(ethylene glycol) (PEG) is frequently used for liposomal surface modification. However, as PEGylated liposomes are cleared rapidly from circulation upon repeated injections, substitutes of PEG are being sought. We focused on a water-soluble polymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) units, and synthesized poly(MPC) (PMPC)-conjugated lipid (PMPC-lipid) with degrees of MPC polymerization ranging from 10 to 100 (calculated molecular weight: 3 to 30 kDa). In addition, lipids with three different alkyl chains, myristoyl, palmitoyl, and stearoyl, were applied for liposomal surface coating. We studied the interactions of PMPC-lipids with plasma albumin, human complement protein C3 and fibrinogen using a quartz crystal microbalance with energy dissipation, and found that adsorption of albumin, C3 and fibrinogen could be suppressed by coating with PMPC-lipids. In particular, the effect was more pronounced for PMPC chains with higher molecular weight. We evaluated the size, polydispersity index, surface charge, and membrane fluidity of the PMPC-lipid-modified liposomes. We found that the effect of the coating on the dispersion stability was maintained over a long period (98 days). Furthermore, we also demonstrated that the anti-PEG antibody did not interact with PMPC-lipids. Thus, our findings suggest that PMPC-lipids can be used for liposomal coating.

    Place, publisher, year, edition, pages
    Royal Society of ChemistryRoyal Society of Chemistry (RSC), 2021
    National Category
    Physical Chemistry
    Identifiers
    urn:nbn:se:uu:diva-469709 (URN)10.1039/d1bm00570g (DOI)000674760600001 ()34286724 (PubMedID)
    Funder
    Swedish Research Council, 2018-04199Swedish Research Council, 2016-2075-5.1Swedish Research Council, 2016-04519The Swedish Foundation for International Cooperation in Research and Higher Education (STINT)VinnovaEU, Horizon 2020
    Available from: 2022-03-14 Created: 2022-03-14 Last updated: 2024-01-15Bibliographically approved
    4. Effect of liposome surface modification with water-soluble phospholipid polymer chain-conjugated lipids on interaction with human plasma proteins
    Open this publication in new window or tab >>Effect of liposome surface modification with water-soluble phospholipid polymer chain-conjugated lipids on interaction with human plasma proteins
    Show others...
    2022 (English)In: Journal of materials chemistry. B, ISSN 2050-750X, E-ISSN 2050-7518, Vol. 10, no 14, p. 2512-2522Article in journal (Refereed) Published
    Abstract [en]

    Alternative liposome surface coatings for PEGylation to evade the immune system, particularly the complement system, have garnered significant interest. We previously reported poly(2-methacryloyloxyethyl phosphorylcholine) (MPC)-based lipids (PMPC-lipids) and investigated the surface modification of liposomes. In this study, we synthesize PMPC-lipids with polymerization degrees of 10 (MPC10-lipid), 20 (MPC20-lipid), 50 (MPC50-lipid), and 100 (MPC100-lipid), and coated liposomes with 1, 5, or 10 mol% PMPC-lipids (PMPC-liposomes). Non-modified and PEGylated liposomes are used as controls. We investigate the liposome size, surface charge, polydispersity index, and adsorption of plasma proteins to the liposomes post incubation in human plasma containing N,N,N ',N '-ethylenediamine tetraacetic acid (EDTA) or lepirudin by some methods such as sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), western blotting, and automated capillary western blot, with emphasis on the binding of complement protein C3. It is shown that the coating of liposome PMPC-lipids can suppress protein adsorption more effectively with an increase in the molecular weight and molar ratio (1-10 mol%). Apolipoprotein A-I is detected on PMPC-liposomes with a higher molecular weight and higher molar ratio of PMPC-lipids, whereas alpha(2)-macroglobulin is detected on non-modified, PEGylated, and PMPC-liposomes with a shorter polymer chain. In addition, a correlation is shown among the PMPC molecular weight, molar ratio, and C3 binding. The MPC10-lipid cannot inhibit C3 binding efficiently, whereas surface modifications with 10 mol% MPC20-lipid and 5 mol% and 10 mol% MPC50-lipid suppress both total protein and C3 binding. Hence, liposome modification with PMPC-lipids can be a possible strategy for avoiding complement activation.

    Place, publisher, year, edition, pages
    Royal Society of ChemistryRoyal Society of Chemistry (RSC), 2022
    National Category
    Physical Chemistry
    Identifiers
    urn:nbn:se:uu:diva-478350 (URN)10.1039/d1tb01485d (DOI)000704923100001 ()34617092 (PubMedID)
    Funder
    Swedish Research Council, 2018-04199Swedish Research Council, 2016-2075-5.1Swedish Research Council, 2016-04519EU, Horizon 2020Vinnova
    Available from: 2022-06-23 Created: 2022-06-23 Last updated: 2024-12-03Bibliographically approved
    5. Regulation of the innate immune system by fragmented heparin-conjugated lipids on lipid bilayered membranes in vitro
    Open this publication in new window or tab >>Regulation of the innate immune system by fragmented heparin-conjugated lipids on lipid bilayered membranes in vitro
    Show others...
    2023 (English)In: Journal of materials chemistry. B, ISSN 2050-750X, E-ISSN 2050-7518, Vol. 11, no 46, p. 11121-11134Article in journal (Refereed) Published
    Abstract [en]

    Surface modification with heparin is a powerful biomaterial coating strategy that protects against innate immunity activation since heparin is a part of the proteoglycan heparan sulfate on cell surfaces in the body. We studied the heparinization of cellular and material surfaces via lipid conjugation to a heparin-binding peptide. In the present study, we synthesized fragmented heparin (fHep)-conjugated phospholipids and studied their regulation of the innate immune system on a lipid bilayered surface using liposomes. Liposomes have versatile applications, such as drug-delivery systems, due to their ability to carry a wide range of molecules. Owing to their morphological similarity to cell membranes, they can also be used to mimic a simple cell-membrane to study protein–lipid interactions. We investigated the interaction of complement-regulators, factor H and C4b-binding protein (C4BP), as well as the coagulation inhibitor antithrombin (AT), with fHep-lipids on the liposomal surface. Herein, we studied the ability of fHep-lipids to recruit factor H, C4BP, and AT using a quartz crystal microbalance with dissipation monitoring. With dynamic light scattering, we demonstrated that liposomes could be modified with fHep-lipids and were stable up to 60 days at 4 °C. Using a capillary western blot-based method (Wes), we showed that fHep-liposomes could recruit factor H in a model system using purified proteins and assist in the degradation of the active complement protein C3b to iC3b. Furthermore, we found that fHep-liposomes could recruit factor H and AT from human plasma. Therefore, the use of fHep-lipids could be a potential coating for liposomes and cell surfaces to regulate the immune system on the lipid surface.

    Place, publisher, year, edition, pages
    Royal Society of Chemistry, 2023
    National Category
    Immunology in the medical area Biochemistry and Molecular Biology Materials Chemistry
    Identifiers
    urn:nbn:se:uu:diva-499229 (URN)10.1039/D3TB01721D (DOI)001103685900001 ()37953734 (PubMedID)
    Funder
    The Swedish Foundation for International Cooperation in Research and Higher Education (STINT)Swedish Research Council, 2018-04199EU, Horizon 2020Vinnova
    Note

    Title in the list of papers of Anna Adler's thesis: Regulation of innate immune system by fragmented heparin-conjugated lipids on lipid bilayer membranes

    Available from: 2023-03-24 Created: 2023-03-24 Last updated: 2024-02-08Bibliographically approved
    Download full text (pdf)
    UUThesis_A-Adler-2023
    Download (jpg)
    preview image
  • 2.
    Adler, Anna
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Fritsch, Marlene
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Fromell, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Leneweit, Gero
    Carl Gustav Carus-Institute, Association for the Promotion of Cancer Therapy, Niefern-Öschelbronn, Germany.
    Ekdahl, Kristina N.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Linnaeus Center of Biomaterials Chemistry, Linnaeus University, SE-391 82 Kalmar, Sweden.
    Nilsson, Bo
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Teramura, Yuji
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Cellular and Molecular Biotechnology Research Institute (CMB), National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba Central Fifth, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan; Master's/Doctoral Program in Life Science Innovation (T-LSI), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan.
    Regulation of the innate immune system by fragmented heparin-conjugated lipids on lipid bilayered membranes in vitro2023In: Journal of materials chemistry. B, ISSN 2050-750X, E-ISSN 2050-7518, Vol. 11, no 46, p. 11121-11134Article in journal (Refereed)
    Abstract [en]

    Surface modification with heparin is a powerful biomaterial coating strategy that protects against innate immunity activation since heparin is a part of the proteoglycan heparan sulfate on cell surfaces in the body. We studied the heparinization of cellular and material surfaces via lipid conjugation to a heparin-binding peptide. In the present study, we synthesized fragmented heparin (fHep)-conjugated phospholipids and studied their regulation of the innate immune system on a lipid bilayered surface using liposomes. Liposomes have versatile applications, such as drug-delivery systems, due to their ability to carry a wide range of molecules. Owing to their morphological similarity to cell membranes, they can also be used to mimic a simple cell-membrane to study protein–lipid interactions. We investigated the interaction of complement-regulators, factor H and C4b-binding protein (C4BP), as well as the coagulation inhibitor antithrombin (AT), with fHep-lipids on the liposomal surface. Herein, we studied the ability of fHep-lipids to recruit factor H, C4BP, and AT using a quartz crystal microbalance with dissipation monitoring. With dynamic light scattering, we demonstrated that liposomes could be modified with fHep-lipids and were stable up to 60 days at 4 °C. Using a capillary western blot-based method (Wes), we showed that fHep-liposomes could recruit factor H in a model system using purified proteins and assist in the degradation of the active complement protein C3b to iC3b. Furthermore, we found that fHep-liposomes could recruit factor H and AT from human plasma. Therefore, the use of fHep-lipids could be a potential coating for liposomes and cell surfaces to regulate the immune system on the lipid surface.

    Download full text (pdf)
    fulltext
  • 3.
    Andraos, Rama
    et al.
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linköping, Sweden..
    Ahmad, Awais
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Clin Immunol & Transfus Med, Linköping, Sweden..
    Wirestam, Lina
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linköping, Sweden..
    Dahle, Charlotte
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Clin Immunol & Transfus Med, Linköping, Sweden..
    Frodlund, Martina
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linköping, Sweden..
    Rönnelid, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Kastbom, Alf
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linköping, Sweden..
    Sjöwall, Christopher
    Linköping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linköping, Sweden..
    Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals2024In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 11, article id 1455673Article in journal (Refereed)
    Abstract [en]

    Background: Anti-nuclear antibodies (ANA) assessed by immunofluorescence (IF) microscopy are associated with systemic autoimmune rheumatic diseases (SARD) and can be detected years before onset of clinical symptoms. Recent data indicate dysregulation of the immune system with increased levels of proinflammatory cytokines, including type I interferons (IFN), in ANA-positive versus ANA-negative individuals. Herein, the aims were to investigate IF-ANA, ANA fine specificities, and IFN-α protein levels in relation to self-reported symptoms, as well as clinical signs, of SARD in a large group of healthy blood donors (HBD).

    Methods: Sera from 825 HBD (48.8% females) were included. IF-ANA was assessed, using HEp-2 cells, according to the routine at the accredited laboratory of Clinical Immunology, Linköping University Hospital. All samples were analyzed for IgG-ANA fine specificities using addressable laser bead assay (ALBIA) at the same laboratory. IFN-α was determined using ELISA. Antibody-positive individuals, and their sex- and age-matched antibody-negative controls, were asked to fill a questionnaire regarding symptoms associated with SARD.

    Results: In total, 130 HBD (15.8%) were positive with IF-ANA and/or ALBIA. Anti-U1RNP was significantly more common among women. Generally, self-reported symptoms correlated poorly with IF-ANA and/or ALBIA results. Two females with high levels of Ro60/SSA, Ro52/SSA and IFN-α reported mild sicca symptoms and were diagnosed with Sjögren’s disease after clinical evaluation.

    Conclusion: A considerable proportion of apparently HBD are autoantibody positive, but without clear association to self-reported symptoms. Nevertheless, the combination of autoantibodies, relevant symptoms and high IFN-α levels identified the small proportion of individuals with SARD in the study population.

    Download full text (pdf)
    fulltext
  • 4.
    Aspenström, Pontus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Miro GTPases at the Crossroads of Cytoskeletal Dynamics and Mitochondrial Trafficking2024In: Cells, E-ISSN 2073-4409, Vol. 13, no 7, article id 647Article, review/survey (Refereed)
    Abstract [en]

    Miro GTPases are key components in the machinery responsible for transporting mitochondria and peroxisomes along microtubules, and also play important roles in regulating calcium homeostasis and organizing contact sites between mitochondria and the endoplasmic reticulum. Moreover, Miro GTPases have been shown to interact with proteins that actively regulate cytoskeletal organization and dynamics, suggesting that these GTPases participate in organizing cytoskeletal functions and organelle transport. Derailed mitochondrial transport is associated with neuropathological conditions such as Parkinson's and Alzheimer's diseases. This review explores our recent understanding of the diverse roles of Miro GTPases under cytoskeletal control, both under normal conditions and during the course of human diseases such as neuropathological disorders.

    Download full text (pdf)
    FULLTEXT01
  • 5.
    Barbera, Stefano
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Uppsala University, Science for Life Laboratory, SciLifeLab. Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Raucci, Luisa
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Tassone, Giusy
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Tinti, Laura
    Toscana Life Sci Fdn, I-53100 Siena, Italy..
    Prischi, Filippo
    Univ Essex, Sch Life Sci, Colchester CO4 3SQ, England..
    Santucci, Annalisa
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Mongiat, Maurizio
    IRCCS, Dept Res & Diag, Div Mol Oncol, Ctr Riferimento Oncol Aviano CRO, I-33081 Aviano, Italy..
    Tosi, Gian Marco
    Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, I-53100 Siena, Italy..
    Galvagni, Federico
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Dimberg, Anna
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Pozzi, Cecilia
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy..
    Orlandini, Maurizio
    Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.;Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy..
    Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells2023In: International Journal of Biological Macromolecules, ISSN 0141-8130, E-ISSN 1879-0003, Vol. 224, p. 453-464Article in journal (Refereed)
    Abstract [en]

    Blocking the signaling activated by the plasma membrane receptor CD93 has recently been demonstrated a useful tool in antiangiogenic treatment and oncotherapy. In the proliferating endothelium, CD93 regulates cell adhesion, migration, and vascular maturation, yet it is unclear how CD93 interacts with the extracellular matrix activating signaling pathways involved in the vascular remodeling. Here for the first time we show that in endothelial cells CD93 is structured as a dimer and that this oligomeric form is physiologically instrumental for the binding of CD93 to its ligand Multimerin-2. Crystallographic X-ray analysis of recombinant CD93 reveals the crucial role played by the C-type lectin-like and sushi-like domains in arranging as an antiparallel dimer to achieve a functional binding state, providing key information for the future design of new drugs able to hamper CD93 function in neovascular pathologies.

    Download full text (pdf)
    fulltext
  • 6.
    Berglund, Hanna
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Pereira, Beatriz
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Nestor, Marika
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Otolaryngology and Head and Neck Surgery. Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Spiegelberg, Diana
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Otolaryngology and Head and Neck Surgery. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Plastic Surgery. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Therapeutic combination of HSP90 inhibition and radiation therapy reduces tumor growth in a syngeneic neuroblastoma mouse model.Manuscript (preprint) (Other academic)
  • 7.
    Betsholtz, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Dept Med Huddinge, Huddinge, Sweden..
    Toward a granular molecular-anatomic map of the blood vasculature - single-cell RNA sequencing makes the leap2022In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 127, no 1, article id e9051Article, review/survey (Refereed)
    Abstract [en]

    Single-cell RNA sequencing (scRNAseq) marks the birth of a new era in physiology and medicine. Within foreseeable future, we will know exactly what genes are expressed - and at what levels - in all the different cell types and subtypes that make up our bodies. We will also learn how a particular cell state, whether it occurs during development, tissue repair, or disease, reflects precise changes in gene expression. While profoundly impacting all areas of life science, scRNAseq may lead to a particular leap in vascular biology research. Blood vessels pervade and fulfill essential functions in all organs, but the functions differ. Innumerable organ-specific vascular adaptations and specializations are required. These, in turn, are dictated by differential gene expression by the two principal cellular building blocks of blood vessels: endothelial cells and mural cells. An organotypic vasculature is essential for functions as diverse as thinking, gas exchange, urine excretion, and xenobiotic detoxification in the brain, lung, kidney, and liver, respectively. In addition to the organotypicity, vascular cells also differ along the vascular arterio-venous axis, referred to as zonation, differences that are essential for the regulation of blood pressure and flow. Moreover, gene expression-based molecular changes dictate states of cellular activity, necessary for angiogenesis, vascular permeability, and immune cell trafficking, i.e. functions necessary for development, inflammation, and repair. These different levels of cellular heterogeneity create a nearly infinite phenotypic diversity among vascular cells. In this review, I summarize and exemplify what scRNAseq has brought to the picture in just a few years and point out where it will take us.

    Download full text (pdf)
    FULLTEXT01
  • 8.
    Beusch, Christian M.
    et al.
    Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, S-17177 Stockholm, Sweden..
    Simonson, Oscar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Wedin, Johan O
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Sabatier, Pierre
    Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, S-17177 Stockholm, Sweden.;Uppsala Univ, Dept Surg Sci, Cardiothorac Translat Med CTTM Lab, S-75237 Uppsala, Sweden.;Univ Copenhagen, Novo Nord Fdn Ctr Prot Res, DK-2200 Copenhagen, Denmark..
    Felldin, Ulrika
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Kadekar, Sandeep
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
    Osterholm, Cecilia
    Karolinska Inst, Dept Mol Med & Surg, S-17177 Stockholm, Sweden..
    Vegvari, Akos
    Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, S-17177 Stockholm, Sweden..
    Zubarev, Roman A.
    Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, S-17177 Stockholm, Sweden..
    Fromell, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Nilsson, Bo
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    James, Stefan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
    Ståhle, Elisabeth
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Grinnemo, Karl-Henrik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Rodin, Sergey
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery. Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthes, S-75185 Uppsala, Sweden..
    Analysis of local extracellular matrix identifies different aetiologies behind bicuspid and tricuspid aortic valve degeneration and suggests therapies2023In: Cellular and Molecular Life Sciences (CMLS), ISSN 1420-682X, E-ISSN 1420-9071, Vol. 80, no 9, article id 268Article in journal (Refereed)
    Abstract [en]

    Aortic valve degeneration (AVD) is a life-threatening condition that has no medical treatment and lacks individual therapies. Although extensively studied with standard approaches, aetiologies behind AVD are unclear. We compared abundances of extracellular matrix (ECM) proteins from excised valve tissues of 88 patients with isolated AVD of normal tricuspid (TAV) and congenital bicuspid aortic valves (BAV), quantified more than 1400 proteins per ECM sample by mass spectrometry, and demonstrated that local ECM preserves molecular cues of the pathophysiological processes. The BAV ECM showed enrichment with fibrosis markers, namely Tenascin C, Osteoprotegerin, and Thrombospondin-2. The abnormal physical stress on BAV may cause a mechanical injury leading to a continuous Tenascin C-driven presence of myofibroblasts and persistent fibrosis. The TAV ECM exhibited enrichment with Annexin A3 (p = 1.1 x 10(-16) and the fold change 6.5) and a significant deficit in proteins involved in high-density lipid metabolism. These results were validated by orthogonal methods. The difference in the ECM landscape suggests distinct aetiologies between AVD of BAV and TAV; warrants different treatments of the patients with BAV and TAV; elucidates the molecular basis of AVD; and implies possible new therapeutic approaches. Our publicly available database (human_avd_ecm.surgsci. uu.se) is a rich source for medical doctors and researchers who are interested in AVD or heart ECM in general. Systematic proteomic analysis of local ECM using the methods described here may facilitate future studies of various tissues and organs in development and disease.

    Download full text (pdf)
    FULLTEXT01
  • 9.
    Bjornholm, Katrine Dahl
    et al.
    Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Solna, Sweden..
    Del Gaudio, Francesca
    Karolinska Inst, Dept Cell & Mol Biol, Solna, Sweden..
    Li, Hao
    Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Solna, Sweden..
    Li, Weihan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden..
    Vazquez-Liebanas, Elisa
    Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden..
    Andaloussi Mäe, Maarja
    Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden..
    Lendahl, Urban
    Karolinska Inst, Dept Cell & Mol Biol, Solna, Sweden..
    Betsholtz, Christer
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden.;Karolinska Inst, Dept Med, Solna, Sweden..
    Nilsson, Per
    Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Solna, Sweden..
    Karlstrom, Helena
    Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Solna, Sweden..
    Vanlandewijck, Michael
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Solna, Sweden.;Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden.;Karolinska Inst, Dept Med, Solna, Sweden..
    A robust and efficient microvascular isolation method for multimodal characterization of the mouse brain vasculature2023In: CELL REPORTS METHODS, ISSN 2667-2375, Vol. 3, no 3, article id 100431Article in journal (Refereed)
    Abstract [en]

    Studying disease-related changes in the brain vasculature is warranted due to its crucial role in supplying oxygen and nutrients and removing waste and due to the anticipated vascular dysfunction in brain dis-eases. To this end, we have developed a protocol for fast and simple isolation of brain vascular fragments without the use of transgenic reporters. We used it to isolate and analyze 22,515 cells by single-cell RNA sequencing. The cells distributed into 23 distinct clusters corresponding to all known vascular and perivas-cular cell types in the brain. Western blot analysis also suggested that the protocol is suitable for proteomic analysis. We further adapted it for the establishment of primary cell cultures. The protocol generated highly reproducible results. In conclusion, we have developed a simple and robust brain vascular isolation proto-col suitable for different experimental modalities, such as single-cell analyses, western blotting, and pri-mary cell culture.

  • 10.
    Brunet-Ratnasingham, Elsa
    et al.
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Morin, Sacha
    Department of Computer Science and Operations Research, Université de Montréal, Montreal, QC, Canada..
    Randolph, Haley E
    Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA..
    Labrecque, Marjorie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Bélair, Justin
    Department of Mathematics and Statistics, Université de Montréal, Montreal, QC, Canada..
    Lima-Barbosa, Raphaël
    Department of Mathematics and Statistics, Université de Montréal, Montreal, QC, Canada..
    Pagliuzza, Amélie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Marchitto, Lorie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Hultström, Michael
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology, Integrative Physiology. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
    Niessl, Julia
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Cloutier, Rose
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Sreng Flores, Alina M
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Brassard, Nathalie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Benlarbi, Mehdi
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Prévost, Jérémie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Ding, Shilei
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Anand, Sai Priya
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Sannier, Gérémy
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Marks, Amanda
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Wågsäter, Dick
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology, Integrative Physiology.
    Bareke, Eric
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Zeberg, Hugo
    Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden..
    Lipcsey, Miklós
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care, Hedenstierna laboratory.
    Frithiof, Robert
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Zhou, Sirui
    Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada..
    Nakanishi, Tomoko
    Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada..
    Morrison, David
    Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada..
    Vezina, Dani
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Bourassa, Catherine
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Gendron-Lepage, Gabrielle
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Medjahed, Halima
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Point, Floriane
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Richard, Jonathan
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Larochelle, Catherine
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Prat, Alexandre
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Cunningham, Janet L
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Psychiatry.
    Arbour, Nathalie
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Durand, Madeleine
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Richards, J Brent
    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada..
    Moon, Kevin
    Department of Mathematics and Statistics, Utah State University, Logan, UT, USA..
    Chomont, Nicolas
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Finzi, Andrés
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Tétreault, Martine
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada..
    Barreiro, Luis
    Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA..
    Wolf, Guy
    Department of Computer Science and Operations Research, Université de Montréal, Montreal, QC, Canada. guy.wolf@umontreal.ca..
    Kaufmann, Daniel E
    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada. daniel.kaufmann@chuv.ch..
    Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity2024In: Nature Communications, E-ISSN 2041-1723, Vol. 15, no 1, article id 4177Article in journal (Refereed)
    Abstract [en]

    Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4+ T cell frequencies. These data suggest that the "Interferon paradox" previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.

    Download full text (pdf)
    fulltext
  • 11.
    Claesson-Welsh, Lena
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Jin, Yi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Tyrosine-protein kinase Yes is essential in vascular barrier dynamics2022In: Nature Cardiovascular Research, ISSN 2731-0590, Vol. 1, no 12, p. 1136-1137Article in journal (Other academic)
    Abstract [en]

    Endothelial cell-cell contacts in blood vessels constitute a barrier to the flux of molecules and cells from blood to tissues. We identified the tyrosine-protein kinase Yes as the principal regulator of collective endothelial cell migration and vascular barrier dynamics, a finding that opens avenues for future therapeutic development.

  • 12.
    Cunningham, Janet L.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Psychiatry.
    Nordmark, Gunnel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology.
    Fällmar, David
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Neuroradiologi.
    Cervenka, Simon
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Psychiatry.
    Gallwitz, Maike
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Psychiatry.
    Säll, Roland
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Psychiatry. Psychiatry, Uppsala University Hospital, Uppsala, Sweden.
    Schmidt, Peter T.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Rönnelid, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Persson, Barbro
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Kindmark, Andreas
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrinology and mineral metabolism.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Neurology.
    Experiences in implementing immunopsychiatry in real life2023In: Journal of Affective Disorders Reports, E-ISSN 2666-9153, Vol. 13, article id 100597Article in journal (Refereed)
    Abstract [en]

    Immunological mechanisms, both alone and in combination, are associated with a broad range of psychiatric disorders encompassing autoimmune, autoinflammatory disorders but also genetic, metabolic, or other immunological disorders. Early treatment improves the outcome for autoimmune disorders, but early diagnosis is more difficult when isolated psychiatric symptoms are manifestations of autoimmunity. Treatment of these cases must encompass integrated models of disease, as both systemic autoimmunity and psychological processes influence mental health. Several challenges need to be overcome to efficiently merge psychiatric and somatic disease paradigms and medical care ranging from language and conceptual barriers to organizational barriers. Since 2015, the Immunopsychiatry team at Uppsala University has developed a collaborative multidisciplinary approach to improve and integrate care for patients with moderate to severe psychiatric disorders. Based on this experience, we have outlined the obstacles to be overcome in taking steps forward to achieve the long-term goal of understanding and early detection and identification of treatable immunological conditions within the psychiatric patient population; the described framework of evaluations and work-flow may serve as a model for other centers.

    Download full text (pdf)
    Experiences in implementing immunopsychiatry in real life
  • 13.
    Cvetkovski, Filip
    et al.
    ITB MED AB, Res & Dev, Stockholm, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Endocrine & Sarcoma Surg Unit, Stockholm, Sweden..
    Razavi, Ronia
    ITB MED AB, Res & Dev, Stockholm, Sweden..
    Sellberg, Felix
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. ITB MED AB, Res & Dev, Stockholm, Sweden..
    Berglund, Erik
    ITB MED AB, Res & Dev, Stockholm, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Endocrine & Sarcoma Surg Unit, Stockholm, Sweden.;Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Transplantat Surg, Stockholm, Sweden..
    Berglund, David
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. ITB MED AB, Res & Dev, Stockholm, Sweden..
    Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro2023In: American Journal of Transplantation, ISSN 1600-6135, E-ISSN 1600-6143, Vol. 23, no 10, p. 1603-1611Article in journal (Refereed)
    Abstract [en]

    Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and abatacept are nondepleting fusion proteins blocking CD28/B7 costimulation, whereas siplizumab is a depleting antiCD2 immunoglobulin G1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with abatacept or belatacept on T cell alloreactivity in mixed lymphocyte reactions was investigated. In contrast to monotherapy, the combination of siplizumab with belatacept or abatacept induced near-complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells compared with monotherapy. Although siplizumab monotherapy leads to significant regulatory T cell enrichment, high doses of cytotoxic T-lymphocyte-associated antigen 4 and a human IgG1 Fc fragment in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with abatacept or belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate when other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation although still allowing for enrichment of regulatory T cells.

    Download full text (pdf)
    fulltext
  • 14.
    Del Gaudio, Francesca
    et al.
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Liu, Dongli
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.;Guangxi Med Univ Nanning, Dept Pediat, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China..
    Andaloussi Mäe, Maarja
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Braune, Eike-Benjamin
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Hansson, Emil M.
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Wang, Qing-Dong
    AstraZeneca, Biosci Cardiovasc Res & Early Dev, Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, Gothenburg, Sweden..
    Betsholtz, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Dept Med, Huddinge, Sweden..
    Lendahl, Urban
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Left ventricular hypertrophy and metabolic resetting in the Notch3-deficient adult mouse heart2023In: Scientific Reports, E-ISSN 2045-2322, Vol. 13, no 1, article id 15022Article in journal (Refereed)
    Abstract [en]

    The heart depends on a functional vasculature for oxygenation and transport of nutrients, and it is of interest to learn how primary impairment of the vasculature can indirectly affect cardiac function and heart morphology. Notch3-deficiency causes vascular smooth muscle cell (VSMC) loss in the vasculature but the consequences for the heart remain largely elusive. Here, we demonstrate that Notch3(-/-) mice have enlarged hearts with left ventricular hypertrophy and mild fibrosis. Cardiomyocytes were hypertrophic but not hyperproliferative, and the expression of several cardiomyocyte markers, including Tnt2, Myh6, Myh7 and Actn2, was altered. Furthermore, expression of genes regulating the metabolic status of the heart was affected: both Pdk4 and Cd36 were downregulated, indicating a metabolic switch from fatty acid oxidation to glucose consumption. Notch3(-/-) mice furthermore showed lower liver lipid content. Notch3 was expressed in heart VSMC and pericytes but not in cardiomyocytes, suggesting that a perturbation of Notch signalling in VSMC and pericytes indirectly impairs the cardiomyocytes. In keeping with this, Pdgfb(ret/ret) mice, characterized by reduced numbers of VSMC and pericytes, showed left ventricular and cardiomyocyte hypertrophy. In conclusion, we demonstrate that reduced Notch3 or PDGFB signalling in vascular mural cells leads to cardiomyocyte dysfunction.

    Download full text (pdf)
    FULLTEXT01
  • 15.
    Ekdahl, Kristina N.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Linnaeus Univ, Linnaeus Ctr Biomat Chem, Kalmar, Sweden.
    Fromell, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Mannes, Marco
    Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany..
    Grinnemo, Karl-Henrik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Thoracic Surgery.
    Huber-Lang, Markus
    Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany..
    Teramura, Yuji
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst CMB, Tsukuba, Ibaraki, Japan; Univ Tsukuba, Masters Doctoral Program Life Sci Innovat T LSI, Tsukuba, Ibaraki, Japan.
    Nilsson, Bo
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Therapeutic regulation of complement activation in extracorporeal circuits and intravascular treatments with special reference to the alternative pathway amplification loop2023In: Immunological Reviews, ISSN 0105-2896, E-ISSN 1600-065X, Vol. 313, no 1, p. 91-103Article, review/survey (Refereed)
    Abstract [en]

    A number of clinical treatment modalities involve contact between blood and biomaterials: these include extracorporeal circuits such as hemodialysis, cardiopulmonary bypass, plasmapheresis, and intravascular treatments. Common side effects arising from these treatments are caused by activation of the cascade systems of the blood. Many of these side effects are mediated via the complement system, including thromboinflammatory reactions and rejection of implants. Depending on the composition of the materials, complement activation is triggered via all the activation pathways but is by far mostly driven by the alternative pathway amplification loop. On biomaterial surfaces the alternative pathway amplification is totally unregulated and leads under optimal conditions to deposition of complement fragments, mostly C3b, on the surface leading to a total masking of the underlying surface. In this review, we discuss the mechanism of the complement activation, clinical consequences of the activation, and potential strategies for therapeutic regulation of the activation, using hemodialysis as demonstrator.

    Download full text (pdf)
    fulltext
  • 16.
    Elbagir, Sahwa
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Diaz-Gallo, Lina-Marcela
    Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden..
    Grosso, Giorgia
    Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden..
    Zickert, Agneta
    Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden..
    Gunnarsson, Iva
    Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden..
    Mahler, Michael
    Werfen Autoimmun, Res & Dev, San Diego, CA USA..
    Svenungsson, Elisabet
    Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden..
    Rönnelid, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE2023In: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 62, no 2, p. 924-933Article in journal (Refereed)
    Abstract [en]

    Objectives: Emerging evidence demonstrates that aPS-PT associate with thrombotic events. Genetic predisposition, including HLA-DRB1 alleles, is known to contribute to the occurrence of conventional aPL [anti-beta(2)glycoprotein-I (anti-beta(2)GPI) and aCL]. We investigated associations between aPS-PT and HLA-DRB1* alleles and thrombosis in SLE. Conventional aPL were included for comparison.

    Methods: We included 341 consecutive SLE patients, with information on general cardiovascular risk factors, including blood lipids, LA and thrombotic events. aPS/PT, anti-beta(2)GPI and aCL of IgA/G/M isotypes and LA were quantified.

    Results: aPS/PT antibodies associated positively with HLA-DRB1*13 [odds ratio (OR) 2.7, P = 0.002], whereas anti-beta(2)GPI and aCL antibodies associated primarily with HLA-DRB1*04 (OR 2.5, P = 0.0005). These associations remained after adjustment for age, gender and other HLA-DRB1* alleles. HLA-DRB1*13, but not DRB1*04, remained as an independent risk factor for thrombosis and APS after adjustment for aPL and cardiovascular risk factors. The association between DRB1*13 and thrombosis was mediated by aPS-PT positivity. HLA-DRB1*03, on the other hand, associated negatively with thrombotic events as well as all aPL using both uni- and multivariate analyses. HLA-DRB1*03 had a thrombo-protective effect in aPL-positive patients. Additionally, HLA-DRB1*03 was associated with a favourable lipid profile regarding high-density lipoprotein and triglycerides.

    Conclusions: HLA-DRB1*13 confers risk for both aPS-PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through aPS-PT. HLA-DRB1*03 was negatively associated with aPL and positively with favourable lipid levels. Thus, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk.

    Download full text (pdf)
    fulltext
  • 17.
    ElBeck, Zaher
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden.
    Hossain, Mohammad Bakhtiar
    Biosci Renal Res & Early Dev, Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, AstraZeneca, Gothenburg, Sweden..
    Siga, Humam
    Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden..
    Oskolkov, Nikolay
    Lund Univ, Dept Biol, Sci Life Lab, Natl Bioinformat Infrastruct Sweden, Lund, Sweden..
    Karlsson, Fredrik
    AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
    Lindgren, Julia
    Translat Genom Ctr Genom Res, Discovery Sci, R&D, Translat Genom,Ctr Genom Res, Gothenburg, Sweden..
    Walentinsson, Anna
    Translat Sci & Expt Med, Res & Early Dev Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, AstraZeneca, Gothenburg, Sweden..
    Koppenhöfer, Dominique
    Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden..
    Jarvis, Rebecca
    Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
    Bürli, Roland
    Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
    Jamier, Tanguy
    Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
    Franssen, Elske
    Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
    Firth, Mike
    AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
    Degasperi, Andrea
    AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden.;Univ Cambridge, Early Canc Inst, Cambridge, England..
    Bendtsen, Claus
    AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
    Menzies, Robert I.
    Biosci Renal Res & Early Dev, Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, AstraZeneca, Gothenburg, Sweden..
    Streckfuss-Bömeke, Katrin
    Univ Wurzburg, Inst Pharmacol & Toxicol, Wurzburg, Germany.;Georg August Univ Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Gottingen, Gottingen, Germany.;Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
    Kohlhaas, Michael
    Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
    Nickel, Alexander G.
    Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
    Lund, Lars H.
    Karolinska Inst, Dept Med, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden..
    Maack, Christoph
    Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
    Végvári, Ákos
    Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, Stockholm, Sweden..
    Betsholtz, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden.
    Epigenetic modulators link mitochondrial redox homeostasis to cardiac function in a sex-dependent manner2024In: Nature Communications, E-ISSN 2041-1723, Vol. 15, no 1, article id 2358Article in journal (Refereed)
    Abstract [en]

    While excessive production of reactive oxygen species (ROS) is a characteristic hallmark of numerous diseases, clinical approaches that ameliorate oxidative stress have been unsuccessful. Here, utilizing multi-omics, we demonstrate that in cardiomyocytes, mitochondrial isocitrate dehydrogenase (IDH2) constitutes a major antioxidative defense mechanism. Paradoxically reduced expression of IDH2 associated with ventricular eccentric hypertrophy is counterbalanced by an increase in the enzyme activity. We unveil redox-dependent sex dimorphism, and extensive mutual regulation of the antioxidative activities of IDH2 and NRF2 by a feedforward network that involves 2-oxoglutarate and L-2-hydroxyglutarate and mediated in part through unconventional hydroxy-methylation of cytosine residues present in introns. Consequently, conditional targeting of ROS in a murine model of heart failure improves cardiac function in sex- and phenotype-dependent manners. Together, these insights may explain why previous attempts to treat heart failure with antioxidants have been unsuccessful and open new approaches to personalizing and, thereby, improving such treatment.

    Download full text (pdf)
    FULLTEXT01
  • 18.
    Faresjö, Rebecca
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
    O Sjöström, Elisabet
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Key2Brain AB, Nanna Svartz Väg 4, Solna, Sweden.
    Berglund, Magnus, M
    Key2Brain AB, Nanna Svartz Väg 4, Solna, Sweden.
    Eriksson, Jonas
    PET Centre, Uppsala University Hospital, Uppsala, Sweden; Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
    Sehlin, Dag
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
    Syvänen, Stina
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
    Single domain antibody conjugated to Aβ-binding scFv penetrates BBB via TfR to interact with AβManuscript (preprint) (Other academic)
    Abstract [en]

    Background: Camelid antibody fragments are interesting for use as radioligands for Positron Emission Tomography (PET), in central nervous system imaging, due to their fast clearance from blood. This study evaluated single variable domain of heavy chain (VHH) antibodies derived from llama, targeting the mouse and human transferrin receptor (TfR) for mediating increased brain uptake. In experiments, VHHs were combined with either a human Fc or with the single chain fragment of the amyloid beta (Aβ) antibody 3D6 (scFv3D6) to investigate intrabrain targeting.

    Methods: One novel and one previously disclosed species cross-reactive VHH towards murine TfR (mTfR) and human TfR (hTfR), as well as two VHHs with selective reactivity to mTfR and hTfR, respectively, were compared. The TfR binders were evaluated as recombinant fusion protein (FP) constructs fused with either a human Fc-fragment (FPFc) or with the Aβ-binding fragment scFv3D6 (FPscFv) at either C- or N-terminal positions of scFv3D6. The above FPs were radiolabeled with iodine-125 (125I) and biodistribution was studied ex vivo at 2 h, 6 h and 24 h after injection in wild-type (WT) mice and AD mouse model AppNL-G-F. Brain, blood, plasma and organ concentrations of the 125I-FPs were measured in a γ-counter. Autoradiography, nuclear track emulsion, and immunohistofluorescence imaging were used to study the brain distribution of the FPs. 

    Results: The constructs based on Fc fusions (FPFc) with binding affinity to mTfR displayed significantly higher brain uptake (around 1-3% ID/gbrain) in comparison with FPFc specific to only hTfR (control; 0.2% ID/gbrain). The VHHs reactive to mTfR fused to a scFv (FPscFv) showed an increased brain uptake 2 h after injection compared to control (FPscFv reactive to hTfR only). FPscFv with VHH linked to the N-terminus of scFv3D6 showed more efficient brain delivery than those fused with the C-terminal of scFv3D6. There was a 17-fold higher brain uptake in AppNL-G-F than WT mice for one of the cross-species  reactive FPscFv (FPscFv1B) at 24 h post-injection, and 2.5-fold higher at 6 h, in ex vivo studies. FPscFv1B  also showed consistently higher relative brain parenchymal localization compared to the other FPs, whether as Fc- or scFv fusion.  

    Conclusion: We showed that the novel cross-reactive VHHs tested herein displayed enhanced brain delivery in mice and that these could be successfully fused with an Aβ-binding scFv-fragment, maintaining high brain and preferential parenchymal delivery with increased retention to Aβ in brain. In summary, a FPscFv construct with affinity towards both  Aβ and mTfR showed differentiated and favorable distribution in AD-mice compared to WT already after 6 h (measured ex vivo); a relevant time point for clinical brain PET.

  • 19.
    Fromell, Karin
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Johansson, Ulrika
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Linnaeus Univ, Linnaeus Ctr Biomat Chem, SE-39182 Kalmar, Sweden..
    Abadgar, Sophia
    Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, S-10691 Stockholm, Sweden.;Stockholm Univ, Dept Environm Sci, S-10691 Stockholm, Sweden..
    Bourzeix, Pauline
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Lundholm, Lovisa
    Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, S-10691 Stockholm, Sweden..
    Elihn, Karine
    Stockholm Univ, Dept Environm Sci, S-10691 Stockholm, Sweden..
    The effect of airborne Palladium nanoparticles on human lung cells, endothelium and blood-A combinatory approach using three in vitro models2023In: Toxicology in Vitro, ISSN 0887-2333, E-ISSN 1879-3177, Vol. 89, article id 105586Article in journal (Refereed)
    Abstract [en]

    A better understanding of the mechanisms behind adverse health effects caused by airborne fine particles and nanoparticles (NP) is essential to improve risk assessment and identification the most critical particle exposures. While the use of automobile catalytic converters is decreasing the exhausts of harmful gases, concentrations of fine airborne particles and nanoparticles (NPs) from catalytic metals such as Palladium (Pd) are reaching their upper safe level. Here we used a combinatory approach with three in vitro model systems to study the toxicity of Pd particles, to infer their potential effects on human health upon inhalation. The three model systems are 1) a lung system with human lung cells (ALI), 2) an endothelial cell system and 3) a human whole blood loop system. All three model systems were exposed to the exact same type of Pd NPs. The ALI lung cell exposure system showed a clear reduction in cell growth from 24 h onwards and the effect persisted over a longer period of time. In the endothelial cell model, Pd NPs induced apoptosis, but not to the same extent as the most aggressive types of NPs such as TiO2. Similarly, Pd triggered clear coagulation and contact system activation but not as forcefully as the highly thrombogenic TiO2 NPs. In summary, we show that our 3-step in vitro model of the human lung and surrounding vessels can be a useful tool for studying pathological events triggered by airborne fine particles and NPs.

    Download full text (pdf)
    fulltext
  • 20.
    Garcia-Gonzalez, Irene
    et al.
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Rocha, Susana F.
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Hamidi, Anahita
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Garcia-Ortega, Lourdes
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Regano, Alvaro
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Sanchez-Munoz, Maria S.
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Lytvyn, Mariya
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Garcia-Cabero, Aroa
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Roig-Soucase, Sergi
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    Schoofs, Hans
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Castro, Marco
    Charite Univ Med Berlin, Ctr Vasc Biomed, Angiogenesis & Metab Lab, Berlin Inst Hlth, Berlin, Germany.;Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany..
    Sabata, Helena
    Josep Carreras Leukaemia Res Inst IJC, Endothelial Pathobiol & Microenvirom Grp, ,Catalonia, Barcelona, ,Catalonia, Spain..
    Potente, Michael
    Charite Univ Med Berlin, Ctr Vasc Biomed, Angiogenesis & Metab Lab, Berlin Inst Hlth, Berlin, Germany.;Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany..
    Graupera, Mariona
    Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Ave Monforte de Lemos 5, Madrid 28029, Spain.;ICREA, Inst Catalana Recerca Estudis & Avancats, Pg Lluis Companys 23, Barcelona, Spain.;Univ Helsinki, Translat Canc Med Program, Res Programs Unit, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00014, Finland..
    Mäkinen, Taija
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Univ Helsinki, Translat Canc Med Program, Res Programs Unit, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki 00014, Finland.;Wihuri Res Inst, Haartmaninkatu 8, 00290 Helsinki, Finland..
    Benedito, Rui
    Ctr Nacl Invest Cardiovasc CNIC, Mol Genet Angiogenesis Grp, Madrid, Spain..
    iSuRe-HadCre is an essential tool for effective conditional genetics2024In: Nucleic Acids Research, ISSN 0305-1048, E-ISSN 1362-4962, Vol. 52, no 13Article in journal (Refereed)
    Abstract [en]

    Methods for modifying gene function at high spatiotemporal resolution in mice have revolutionized biomedical research, with Cre-loxP being the most widely used technology. However, the Cre-loxP technology has several drawbacks, including weak activity, leakiness, toxicity, and low reliability of existing Cre-reporters. This is mainly because different genes flanked by loxP sites (floxed) vary widely in their sensitivity to Cre-mediated recombination. Here, we report the generation, validation, and utility of iSuRe-HadCre, a new dual Cre-reporter and deleter mouse line that avoids these drawbacks. iSuRe-HadCre achieves this through a novel inducible dual-recombinase genetic cascade that ensures that cells expressing a fluorescent reporter had only transient Cre activity, that is nonetheless sufficient to effectively delete floxed genes. iSuRe-HadCre worked reliably in all cell types and for the 13 floxed genes tested. This new tool will enable the precise, efficient, and trustworthy analysis of gene function in entire mouse tissues or in single cells. Graphical Abstract

    Download full text (pdf)
    fulltext
  • 21.
    Gillnäs, Sara
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Gallini, Radiosa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    He, Liqun
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Betsholtz, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Andrae, Johanna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Severe cerebellar malformations in mutant mice demonstrate a role for PDGF-C/PDGFR alpha signalling in cerebellar development2022In: BIOLOGY OPEN, ISSN 2046-6390, Vol. 11, no 8, article id bio059431Article in journal (Refereed)
    Abstract [en]

    Formation of the mouse cerebellum is initiated in the embryo and continues for a few weeks after birth. Double-mutant mice lacking platelet-derived growth factor C (PDGF-C) and that are heterozygous for platelet-derived growth factor receptor alpha (Pdgfc(-/-); Pdgfra(GFP/+)) develop cerebellar hypoplasia and malformation with loss of cerebellar lobes in the posterior vermis. This phenotype is similar to those observed in Foxc1 mutant mice and in a human neuroimaging pattern called Dandy Walker malformation. Pdgfc-Pdgfra mutant mice also display ependymal denudation in the fourth ventricle and gene expression changes in cerebellar meninges, which coincide with the first visible signs of cerebellar malformation. Here, we show that PDGF-C/PDGFR alpha signalling is a critical component in the network of molecular and cellular interactions that take place between the developing meninges and neural tissues, and which are required to build a fully functioning cerebellum.

    Download full text (pdf)
    fulltext
  • 22.
    Globisch, Maria A.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Onyeogaziri, Favour C.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Jauhiainen, Suvi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Yau, Anthony C. Y.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Orsenigo, Fabrizio
    Vascular Biology Unit, IFOM ETS—The AIRC Institute of Molecular Oncology, Milan, Italy.
    Conze, Lei L.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Arce, Maximiliano
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Corada, Monica
    Vascular Biology Unit, IFOM ETS—The AIRC Institute of Molecular Oncology, Milan, Italy.
    Smith, Ross O.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Rorsman, Charlotte
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Sundell, Veronica
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Fernando, Dinesh
    Department of Biomaterials and Technology/Wood Science, Swedish University of Agricultural Sciences, Uppsala, Sweden.
    Daniel, Geoffrey
    Department of Biomaterials and Technology/Wood Science, Swedish University of Agricultural Sciences, Uppsala, Sweden.
    Mattsson, Oscar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Savander, Henri
    Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
    Wanders, Alkwin
    Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
    Rezai Jahromi, Behnam
    Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
    Laakso, Aki
    Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
    Niemelä, Mika
    Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
    Dejana, Elisabetta
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Vascular Biology Unit, IFOM ETS—The AIRC Institute of Molecular Oncology, Milan, Italy.
    Magnusson, Peetra U.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation2022In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 140, no 20, p. 2154-2169Article in journal (Refereed)
    Abstract [sv]

    Cerebral cavernous malformation (CCM) is a neurovascular disease that results in various neurological symptoms. Thrombi have been reported in surgically resected CCM patient biopsies, but the molecular signatures of these thrombi remain elusive. Here, we investigated the kinetics of thrombi formation in CCM and how thrombi affect the vasculature and contribute to cerebral hypoxia. We used RNA sequencing to investigate the transcriptome of mouse brain endothelial cells with an inducible endothelial-specific Ccm3 knock-out (Ccm3-iECKO). We found that Ccm3-deficient brain endothelial cells had a higher expression of genes related to the coagulation cascade and hypoxia when compared with wild-type brain endothelial cells. Immunofluorescent assays identified key molecular signatures of thrombi such as fibrin, von Willebrand factor, and activated platelets in Ccm3-iECKO mice and human CCM biopsies. Notably, we identified polyhedrocytes in Ccm3-iECKO mice and human CCM biopsies and report it for the first time. We also found that the parenchyma surrounding CCM lesions is hypoxic and that more thrombi correlate with higher levels of hypoxia. We created an in vitro model to study CCM pathology and found that human brain endothelial cells deficient for CCM3 expressed elevated levels of plasminogen activator inhibitor-1 and had a redistribution of von Willebrand factor. With transcriptomics, comprehensive imaging, and an in vitro CCM preclinical model, this study provides experimental evidence that genes and proteins related to the coagulation cascade affect the brain vasculature and promote neurological side effects such as hypoxia in CCMs. This study supports the concept that antithrombotic therapy may be beneficial for patients with CCM.

    Download full text (pdf)
    fulltext
  • 23.
    Globisch, Maria Ascención
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Inflammation and immunothrombosis in cerebral cavernous malformation: Novel molecular targets for the treatment of an incurable disease2023Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Cerebral cavernous malformation (CCM) is a vascular disease that causes mulberry-like lesions (cavernomas) in the central nervous system (CNS). Cavernomas are fragile, leaky and prone to rupture which may cause symptoms such as epileptic seizures, focal neurological deficits and hemorrhagic strokes. CCM lesions can appear sporadically in 0.5% of the general population. Alternatively, CCM lesions appear as a consequence of a loss-of-function germline mutation in either CCM1, CCM2, or CCM3 in endothelial cells of the CNS. Inherited CCM is termed familial, and it affects approximately one in ten thousand individuals in an autosomal dominant manner. The aim of this thesis project is to identify novel cell and molecular mechanisms that contribute to the development and progression of cavernous malformations. Additionally, this thesis project aims to identify and validate inhibitors that may reduce lesions and alleviate the side effects in CCM. In this thesis project, two inducible endothelial specific Ccm3 deficient mouse models (acute and chronic) were evaluated with methods such as RNA-sequencing, immunofluorescence, ELISA, scanning and transmission electron microscopy, flow cytometry, and in situ hybridization. Moreover, in vitro cell cultures were used with methods such as immunofluorescence, qPCR, and western blot. Importantly, sporadic and familial human CCM samples were used to show the clinical relevance of our studies. In paper I we focused on the role and kinetics of inflammation in CCM. We analyzed the transcriptome of healthy and Ccm3 deficient mouse brain endothelial cells and found that genes related to inflammation were upregulated in CCM pathology. We identified various inflammatory cytokines in vivo and also identified neutrophils as the most prominent immune cell subtype in CCM. Moreover, we found that neutrophils in CCM produce neutrophil extracellular traps (NETs), that can be inhibited with DNase I. The inhibition of NETs stabilized cavernoma vasculature by reducing fibrinogen and IgG leakage. In paper II we re-used the acute RNA-seq database from paper 1 and focused on endothelial hemostasis and hypoxia. We found that genes related to procoagulation, anticoagulation, and hypoxia were highly upregulated in Ccm3 deficient mice. We validated the findings in vivo and found that the hemostatic system in CCM is dysregulated and that it causes, bleeding, thrombosis, and cerebral hypoxia. In paper III we evaluated the effect of propranolol in CCM. We treated chronic CCM mice with the beta-blocker propranolol and found that propranolol was able to reduce lesions in the brains and retinas of CCM mice as well as reduce cadaverine leakage. Importantly, we identified endothelial plasmalemmal pits and a thick basal membrane between endothelial cells and pericytes, pathological features which reduced upon propranolol treatment. Altogether this thesis significantly contributes to the CCM field as it identified pathological features of cavernomas such as neutrophils with NETs, endothelial plasmalemmal pits, and polyhedrocytes. This thesis work also evaluated pharmacological inhibitors (DNase I and propranolol) in mouse models of CCM and supports the use of anticoagulant therapies in patients with CCM.

    List of papers
    1. Inflammation and neutrophil extracellular traps in cerebral cavernous malformation
    Open this publication in new window or tab >>Inflammation and neutrophil extracellular traps in cerebral cavernous malformation
    Show others...
    2022 (English)In: Cellular and Molecular Life Sciences (CMLS), ISSN 1420-682X, E-ISSN 1420-9071, Vol. 79, no 4, article id 206Article in journal (Refereed) Published
    Abstract [en]

    Cerebral Cavernous Malformation (CCM) is a brain vascular disease with various neurological symptoms. In this study, we describe the inflammatory profile in CCM and show for the first time the formation of neutrophil extracellular traps (NETs) in rodents and humans with CCM. Through RNA-seq analysis of cerebellum endothelial cells from wild-type mice and mice with an endothelial cell-specific ablation of the Ccm3 gene (Ccm3(iECKO)), we show that endothelial cells from Ccm3(iECKO) mice have an increased expression of inflammation-related genes. These genes encode proinflammatory cytokines and chemokines, as well as adhesion molecules, which promote recruitment of inflammatory and immune cells. Similarly, immunoassays showed elevated levels of these cytokines and chemokines in the cerebellum of the Ccm3(iECKO) mice. Consistently, both flow cytometry and immunofluorescence analysis showed infiltration of different subsets of leukocytes into the CCM lesions. Neutrophils, which are known to fight against infection through different strategies, including the formation of NETs, represented the leukocyte subset within the most pronounced increase in CCM. Here, we detected elevated levels of NETs in the blood and the deposition of NETs in the cerebral cavernomas of Ccm3(iECKO) mice. Degradation of NETs by DNase I treatment improved the vascular barrier. The deposition of NETs in the cavernomas of patients with CCM confirms the clinical relevance of NETs in CCM.

    Place, publisher, year, edition, pages
    Springer NatureSpringer Nature, 2022
    Keywords
    Inflammation, Neutrophil extracellular traps, Endothelial cells, Cerebral cavernous malformations
    National Category
    Cell and Molecular Biology
    Identifiers
    urn:nbn:se:uu:diva-472756 (URN)10.1007/s00018-022-04224-2 (DOI)000773261800003 ()35333979 (PubMedID)
    Funder
    Swedish Research Council, 2013-9279Knut and Alice Wallenberg FoundationEU, European Research Council, 74292Swedish Research Council
    Available from: 2022-04-19 Created: 2022-04-19 Last updated: 2024-01-15Bibliographically approved
    2. Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation
    Open this publication in new window or tab >>Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation
    Show others...
    2022 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 140, no 20, p. 2154-2169Article in journal (Refereed) Published
    Abstract [sv]

    Cerebral cavernous malformation (CCM) is a neurovascular disease that results in various neurological symptoms. Thrombi have been reported in surgically resected CCM patient biopsies, but the molecular signatures of these thrombi remain elusive. Here, we investigated the kinetics of thrombi formation in CCM and how thrombi affect the vasculature and contribute to cerebral hypoxia. We used RNA sequencing to investigate the transcriptome of mouse brain endothelial cells with an inducible endothelial-specific Ccm3 knock-out (Ccm3-iECKO). We found that Ccm3-deficient brain endothelial cells had a higher expression of genes related to the coagulation cascade and hypoxia when compared with wild-type brain endothelial cells. Immunofluorescent assays identified key molecular signatures of thrombi such as fibrin, von Willebrand factor, and activated platelets in Ccm3-iECKO mice and human CCM biopsies. Notably, we identified polyhedrocytes in Ccm3-iECKO mice and human CCM biopsies and report it for the first time. We also found that the parenchyma surrounding CCM lesions is hypoxic and that more thrombi correlate with higher levels of hypoxia. We created an in vitro model to study CCM pathology and found that human brain endothelial cells deficient for CCM3 expressed elevated levels of plasminogen activator inhibitor-1 and had a redistribution of von Willebrand factor. With transcriptomics, comprehensive imaging, and an in vitro CCM preclinical model, this study provides experimental evidence that genes and proteins related to the coagulation cascade affect the brain vasculature and promote neurological side effects such as hypoxia in CCMs. This study supports the concept that antithrombotic therapy may be beneficial for patients with CCM.

    Place, publisher, year, edition, pages
    American Society of HematologyAmerican Society of Hematology, 2022
    National Category
    Hematology Neurology
    Research subject
    Immunology
    Identifiers
    urn:nbn:se:uu:diva-489038 (URN)10.1182/blood.2021015350 (DOI)000916621900011 ()35981497 (PubMedID)
    Funder
    Swedish Research Council, 2013-9279Swedish Research Council, 2021-01919Knut and Alice Wallenberg Foundation, 2015-0030EU, European Research Council, 74292
    Available from: 2022-11-25 Created: 2022-11-25 Last updated: 2024-01-15Bibliographically approved
    3. Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study
    Open this publication in new window or tab >>Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study